Friday, after 16 years and $2.5 billion in investment, the Cambridge, Massachusetts-based company Alnylam finally turned a 1998 biology breakthrough into a medicine: a drug called Onpattro to treat the destruction of nerves that results from a rare disease, hATTR amyloidosis, thought to afflict about 50,000 people worldwide.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,